Teva Pharmaceutical Industries Limited (0LER.L)
| Previous close | 7.35 |
| Open | 7.31 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 7.29 - 7.33 |
| 52-week range | 7.10 - 11.25 |
| Volume | |
| Avg. volume | 13,204 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
TEL AVIV, Israel, May 08, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024.
- Business Wire
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, May 08, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo. Results demonstrated that TEV-‘749 met its primary endpoint as measured by a change in the
- Business Wire
Teva to Present at the 2024 Bank of America Healthcare Conference
TEL AVIV, Israel, May 02, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time).
